Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier P Gisbert

Showing results (471-480 of 568) with videos related to

Pageof 57
Sort By:
Journal of Crohn'S & Colitis|December 4, 2013
Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care UnitsXavier Calvet, Julián Panés, Noelia Alfaro, et al.
Terapevticheskii Arkhiv|April 1, 2016
[European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian centers]D S Bordin, O B Yanova, R A Abdulkhakov, et al.
United European Gastroenterology Journal|August 2, 2024
Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countriesPatricio Medel-Jara, Diego Reyes Placencia, Eduardo Fuentes-López, et al.
United European Gastroenterology Journal|February 29, 2024
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international studyMariangela Allocca, Gaia Catalano, Edoardo V Savarino, et al.
Gut|July 11, 2025
<i>Helicobacter pylori</i> antibiotic resistance: a global challenge in search of solutionsChristian Schulz, Jyh-Ming Liou, Mohamed Alboraie, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's diseaseMaría Chaparro, Adrià Aterido, Iván Guerra, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case SeriesStefano Festa, Giulia Zerboni, Lauranne A A P Derikx, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 10, 2022
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryMíriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, et al.
The Lancet. Gastroenterology & Hepatology|March 5, 2023
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology CommissionJohan Burisch, Mirabella Zhao, Selwyn Odes, et al.
Inflammatory Bowel Diseases|April 23, 2019
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA RegistryFiorella Cañete, Míriam Mañosa, María José Casanova, et al.
Pageof 57

Showing results (471-480 of 568) with videos related to

Sort By:
Pageof 57
Journal of Crohn'S & Colitis|December 4, 2013
Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care UnitsXavier Calvet, Julián Panés, Noelia Alfaro, et al.
Terapevticheskii Arkhiv|April 1, 2016
[European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian centers]D S Bordin, O B Yanova, R A Abdulkhakov, et al.
United European Gastroenterology Journal|August 2, 2024
Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countriesPatricio Medel-Jara, Diego Reyes Placencia, Eduardo Fuentes-López, et al.
United European Gastroenterology Journal|February 29, 2024
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international studyMariangela Allocca, Gaia Catalano, Edoardo V Savarino, et al.
Gut|July 11, 2025
<i>Helicobacter pylori</i> antibiotic resistance: a global challenge in search of solutionsChristian Schulz, Jyh-Ming Liou, Mohamed Alboraie, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's diseaseMaría Chaparro, Adrià Aterido, Iván Guerra, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case SeriesStefano Festa, Giulia Zerboni, Lauranne A A P Derikx, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 10, 2022
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryMíriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, et al.
The Lancet. Gastroenterology & Hepatology|March 5, 2023
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology CommissionJohan Burisch, Mirabella Zhao, Selwyn Odes, et al.
Inflammatory Bowel Diseases|April 23, 2019
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA RegistryFiorella Cañete, Míriam Mañosa, María José Casanova, et al.
Pageof 57